{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038981","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.203250+00:00","generated_at":"2026-05-17T18:13:18.359699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ginkgo Q2 2025 revenue $50M, net loss $60M; achieves $250M cost savings goal ahead of schedule","bullets":["Total revenue $50M, down from $56M YoY; Cell Engineering rev up 8% to $39M; Biosecurity down to $10M.","GAAP net loss $60M, improved from $217M YoY; Adjusted EBITDA -$28M, up from -$99M.","Achieved $250M annualized cost reduction target three months ahead of schedule.","Cash, equivalents, marketable securities $474M as of June 30, 2025.","Reaffirmed FY2025 total revenue outlook $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038981","json":"https://secwatch.observer/filing/0001628280-25-038981.json","markdown":"https://secwatch.observer/filing/0001628280-25-038981.md","text":"https://secwatch.observer/filing/0001628280-25-038981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828025038981/0001628280-25-038981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828025038981/dna-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:13:18.359699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}